Model-informed drug development of Mim8 – a next-generation bispecific antibody for treatment of haemophilia A

This publication has 31 references indexed in Scilit:

• Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development
  Clinical Pharmacology & Therapeutics, 2024
• Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action
  Clinical Pharmacokinetics, 2024
• FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic
  Journal of Thrombosis and Haemostasis, 2023
• The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste
  Research and Practice in Thrombosis and Haemostasis, 2023
• Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
  Clinical Pharmacokinetics, 2021
• Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
  Rheumatology and Therapy, 2020
• Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
  Clinical Pharmacokinetics, 2020
• Pharmacokinetics and Clinical Pharmacology of Monoclonal Antibodies in Pediatric Patients
  Pediatric Drugs, 2020
• A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
  Clinical Pharmacokinetics, 2017
• Evaluating the impact of obesity on safety and efficacy of weight-based norepinephrine dosing in septic shock: A single-center, retrospective study
  Intensive and Critical Care Nursing, 2017